
MHRA approves myopia treatment for children in UK
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved Ryjunea (low-dose atropine) to slow the progression of myopia in children. The drug, developed by pharmaceutical company Santen, becomes the first licensed treatment to slow childhood myopia. The approval follows authorisation by the European Commission and… Read More
